ストックスクリーナーアプリを入手
6.35
4.79%
0.29
アフターアワーズ：
6.35
前日終値:
$6.06
開ける：
$6.03
24時間の取引高:
174.42K
Relative Volume:
0.73
時価総額：
$150.21M
収益：
-
当期純損益:
$-51.50M
株価収益率:
-25.40
EPS:
-0.25
ネットキャッシュフロー:
$-47.10M
1週間 パフォーマンス:
+10.63%
1か月 パフォーマンス:
+21.41%
6か月 パフォーマンス:
-26.16%
1年 パフォーマンス:
-25.71%
1日の値動き範囲:
$6.00
$6.36
1週間の範囲:
$5.66
$6.36
52週間の値動き範囲:
$4.61
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
名前
Outlook Therapeutics Inc
セクター
電話
(609) 619-3990
住所
111 S. WOOD AVENUE, ISELIN, NJ
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-03 | 開始されました | Guggenheim | Buy |
| 2023-02-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 開始されました | BTIG Research | Buy |
| 2022-09-13 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-05-16 | 開始されました | Oppenheimer | Outperform |
| 2019-04-22 | 開始されました | Ascendiant Capital Markets | Buy |
すべてを表示
Outlook Therapeutics Inc (OTLK) 最新ニュース
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
(OTLK) Trading Signals - Stock Traders Daily
Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat
Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com
How the (OTLK) price action is used to our Advantage - Stock Traders Daily
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com
ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews
OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(OTLK) On The My Stocks Page - Stock Traders Daily
Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India
Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com
Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com
Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
(OTLK) Investment Analysis - Stock Traders Daily
Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Outlook Therapeutics Inc (OTLK)’s Performance - The Dwinnex
A year in review: Outlook Therapeutics Inc (OTLK)’s performance in the last year - US Post News
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - ForexTV.com
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics Inc (OTLK) Becoming More Attractive for Investors - Knox Daily
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Outlook Therapeutics Inc [OTLK] Shares Jump Approximately 62.65% Over the Year - Knox Daily
Iovance Therapeutics: Historic Product, Tough Commercial Outlook - Seeking Alpha
Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics (NASDAQ:OTLK) Price Target Lowered to $33.00 at Ascendiant Capital Markets - Defense World
China Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook, 2030 - Grand View Research
Ascendiant Capital Markets Lowers Outlook Therapeutics (NASDAQ:OTLK) Price Target to $33.00 - MarketBeat
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Kuwait Gout Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research
OTLK’s latest rating updates from top analysts. - Knox Daily
India Gastrointestinal Therapeutics Market Size & Outlook, 2030 - Grand View Research
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles - Seeking Alpha
Outlook Therapeutics Inc [OTLK] Investment Guide: What You Need to Know - Knox Daily
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Forecasted to Earn FY2024 Earnings of ($3.90) Per Share - MarketBeat
Vanguard Group Inc. Has $4.08 Million Stock Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Vanguard Group Inc. Sells 6,219,100 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia - Yahoo Finance
Outlook Therapeutics Inc (OTLK) 財務データ
収益
当期純利益
現金流量
EPS
Outlook Therapeutics Inc (OTLK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Haddadin Yezan Munther | Director |
Mar 28 '24 |
Buy |
11.82 |
1,882 |
22,242 |
5,049 |
| Evanson Jeff | CHIEF COMMERCIAL OFFICER |
Mar 07 '24 |
Buy |
0.42 |
62,484 |
26,243 |
808,459 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):